

## Optimizing Patient Outcomes in Bipolar Disorder: Long-term Management of Major Depressive Episodes - Twitter Chat #2

### References

American Psychiatric Association. Bipolar disorder. In: *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*. 5th ed. American Psychiatric Association Publishing: Washington, DC; 2013:123-154.

Butler M, Urosevic S, Desai P, et al. *Treatment of Bipolar Disorder in Adults: A Systematic Review*. Rockville, MD: Agency for Healthcare Research and Quality, US Dept of Health and Human Services; 2018. Comparative Effectiveness Review 208.

Citrome L. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract*. 2019;73(10):e13397. doi:10.1111/ijcp.13397

Citrome L. Food and Drug Administration-approved treatments for acute bipolar depression: what we have and what we need. *J Clin Psychopharmacol*. 2020;40(4):334-338. doi:10.1097/JCP.0000000000001227

Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: A Swedish national cohort study. *JAMA Psychiatry*. 2013;70(9):931-939. doi:10.1001/jamapsychiatry.2013.1394

Malhi GS, Basset D, Boyce R, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry*. 2015;49(12):1087-1206. doi:10.1177/0004867415617657

Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. *Arch Gen Psychiatry*. 2011;68(3):241-251. doi:10.1001/archgenpsychiatry.2011.12

Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: a systematic review and network meta-analysis. *World J Biol Psychiatry*. 2018;19(8):586-601. doi:10.1080/15622975.2017.1285050

Pary R, Patel M, Lippmann S. Depression and bipolar disorders in patients with alcohol use disorders. *Fed Pract*. 2017;34(Suppl 2):37S-41S.

Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. *Am J Psychiatry*. 2010;167(6):668-675.

Tolliver BK, Anton RF. Assessment and treatment of mood disorders in the context of substance abuse. *Dialogues Clin Neurosci*. 2015;17(2):181-190.

## **Glossary**

ADHD, attention deficit hyperactive disorder  
AE, adverse event  
CANMAT, Canadian Network for Mood and Anxiety Treatments  
CI, confidence interval  
COPD, chronic obstructive pulmonary disorder  
CVD, cardiovascular disease  
EPS, extrapyramidal symptoms  
HCP, healthcare provider  
HR, hazard ratio  
IR, immediate release  
ISBD, International Society for Bipolar Disorder  
MDE, major depressive episode  
OFC, olanzapine-fluoxetine combination  
Tx, treatment  
w/, with  
XR, extended release